Amicus Therapeutics Announces Third Quarter 2008 Results Release Date

Tuesday, October 28, 2008 General News J E 4
CRANBURY, N.J., Oct. 27 Amicus Therapeutics(Nasdaq: FOLD) will announce third quarter 2008 financial results after theregular close of markets on Monday, November 3, 2008. The results announcementwill be followed by a live conference call and webcast that afternoon at5 p.m. ET.

Interested participants and investors may access the conference call at5 p.m. ET by dialing 877-419-6591 (U.S./Canada) or 719-325-4858(international). A telephonic replay of the call will be available for sevendays beginning at 8 p.m. ET. Access numbers for this replay are 888-203-1112(U.S./Canada) and 719-457-0820 (international); participant code 4499321.

An audio webcast can also be accessed via the investor section of theAmicus Therapeutics Web site at underInvestors: Events and Presentations. Web participants are encouraged to go tothe Web site 15 minutes prior to the start of the call to register, downloadand install any necessary software. After the live webcast, a webcast replaywill remain available in the Investors section of the Amicus Therapeutics Website for 30 days.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oraltherapeutics known as pharmacological chaperones for the treatment of a rangeof human genetic diseases. Pharmacological chaperone technology involves theuse of small molecules that selectively bind to and stabilize proteins incells, leading to improved protein folding and trafficking, and increasedactivity. Amicus is initially targeting lysosomal storage disorders, which aresevere, chronic genetic diseases with unmet medical needs. Amicus hascompleted Phase 2 clinical trials of Amigal for the treatment of Fabry diseaseand is conducting Phase 2 clinical trials of Plicera for the treatment ofGaucher disease and AT2220 for the treatment of Pompe disease.

Amicus' press releases are available at


SOURCE Amicus Therapeutics


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Enbrel(R) (etanercept) Is the First Biologic With ...
Patent Technologies Keep CGMT in a Leading Positio...